| Direct Competitor Comparison | |
|---|
| AKRX | AGN | HSP | NVS | Industry |
|---|
| Market Cap: | 1.43B | 29.21B | 5.94B | 183.38B | 24.96B |
|---|
| Employees: | 759 | 11,100 | 16,000 | 129,000 | 6.50K |
|---|
| Qtrly Rev Growth (yoy): | 0.43 | 0.08 | -0.09 | 0.02 | 0.00 |
|---|
| Revenue (ttm):
| 278.30M | 5.92B | 4.01B | 57.80B | 11.17B |
|---|
| Gross Margin (ttm): | 0.56 | 0.87 | 0.25 | 0.68 | 0.43 |
|---|
| EBITDA (ttm): | 92.34M | 1.87B | 231.40M | 17.15B | 228.10M |
|---|
| Operating Margin (ttm):
| 0.29 | 0.29 | 0.00 | 0.22 | 0.16 |
|---|
| Net Income (ttm): | 43.11M | 1.14B | -72.60M | 9.66B | N/A |
|---|
| EPS (ttm): | 0.39 | 2.88 | -0.44 | 3.94 | 0.51 |
|---|
| P/E (ttm): | 38.12 | 34.22 | N/A | 18.94 | 44.21 |
|---|
| PEG (5 yr expected): | 1.15 | 1.56 | 2.38 | 2.76 | 1.27 |
|---|
| P/S (ttm): | 5.12 | 4.94 | 1.48 | 3.17 | 3.09 |
|---|
|
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 104.24 | 0.00 | 78.18B | 17.64 |
|---|
| Genentech, Inc. | Private |
|---|
| Biogen Idec Inc. | BIIB | 231.33 | 0.00 | 54.91B | 36.71 |
|---|
| Genzyme Corporation | Private |
|---|
| Merck Serono S.A. | Private |
|---|
| Gilead Sciences Inc. | GILD | 56.47 | 0.00 | 86.14B | 31.62 |
|---|
| MedImmune, L.L.C. | Private |
|---|
| Life Technologies Corporation | LIFE | 73.68 | 0.00 | 12.68B | 31.19 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 40.21 | 0.00 | 34.26B | 20.07 |
|---|
| Sandoz International GmbH | Private |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 130.20 | 0.00 | 16.63B | N/A |
|---|
| Ranbaxy Laboratories Limited | Private |
|---|
| Mylan, Inc. | MYL | 31.23 | 0.00 | 11.90B | 20.86 |
|---|
| Pfizer Inc. | PFE | 28.78 | 0.00 | 204.14B | 13.78 |
|---|
| Johnson & Johnson | JNJ | 88.59 | 0.00 | 248.84B | 24.06 |
|---|
| GlaxoSmithKline plc | GSK | 52.65 | 0.00 | 127.52B | 19.24 |
|---|
| Sanofi | SNY | 55.05 | 0.00 | 145.70B | 27.13 |
|---|
| Novartis AG | NVS | 74.63 | 0.00 | 183.38B | 18.94 |
|---|
| Roche Holding AG | RHHBY | 64.71 | 0.00 | 219.62B | 21.66 |
|---|
| AstraZeneca PLC | AZN | 51.71 | 0.00 | 64.64B | 11.44 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 37.72 | 0.00 | 58.80B | 11.50 |
|---|
| Bristol-Myers Squibb Company | BMY | 44.06 | 0.00 | 72.37B | 49.90 |
|---|
|
| News on Direct Competitors | |
|---|
- HSP
- U.S. court ruling favors Cubist in patent case versus Hospira Reuters Mon, May 20
- HSP
- U.S. court ruling favors Cubist in patent case vs Hospira at Reuters Mon, May 20
- NVS
- Actavis buying Warner Chilcott in $8.5B deal AP Mon, May 20
- HSP
- Interesting HSP Put And Call For July at TheStreet Mon, May 20
- AGN
- 4 Stocks Going Ex-Dividend Tomorrow: PGH, NTI, MAT, AGN at TheStreet Mon, May 20
- AGN
- Allergan Stock To Go Ex-dividend Tomorrow (AGN) at TheStreet Mon, May 20
- HSP
- Hospira's former chief scientific officer returns AP Tue, May 14
- NVS
- Hospital to probe East German medical trials AP Mon, May 13
- AGN
- Regeneron Pharma raises sales forecast for Eylea AP Fri, May 3
- AGN
- Allergan slides, Regeneron surges on eye drug news AP Wed, May 1
- AGN
- Allergan shares fall on delay of eye drug study AP Wed, May 1
- HSP
- Hospira takes 1Q loss on medical device charges AP Wed, May 1
- NVS
- Pfizer 1Q profit up, but drugmaker cuts outlook AP Tue, Apr 30
- NVS
- Pfizer Q1 profit up, but drugmaker cuts outlook AP Tue, Apr 30
- NVS
- Novartis posts profit gain thanks to new drugs AP Wed, Apr 24
All Headlines for these symbols... Currency in USD. | |
|
0.47%